Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | TARDBP | Q13148 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL545946 | 1.00 | MEN1 (0.40) | MEN1KMT2AADRB2TARDBPRAB9A | |
| SCHEMBL400464 | 0.95 | CCR3 (0.39) | RAB9ANPC1MAPTPKMSMN1; SMN2 | |
| SCHEMBL402784 | 0.95 | CCR3 (0.39) | RAB9ANPC1MAPTPKMSMN1; SMN2 | |
| SCHEMBL402743 | 0.91 | RAB9A (0.40) | RAB9ANPC1MAPTPKMSMN1; SMN2 | |
| SCHEMBL399032 | 0.90 | KMT2A (0.41) | MEN1KMT2AADRB2TARDBPRAB9A | |
| SCHEMBL4012403 | 0.90 | KMT2A (0.41) | MEN1KMT2AADRB2TARDBPRAB9A | |
| SCHEMBL544986 | 0.90 | KMT2A (0.41) | MEN1KMT2AADRB2TARDBPRAB9A | |
| SCHEMBL402799 | 0.90 | KMT2A (0.40) | MEN1KMT2AADRB2TARDBPRAB9A | |
| SCHEMBL545169 | 0.89 | ADRB2 (0.44) | MEN1KMT2AADRB2TARDBPRAB9A | |
| SCHEMBL4012615 | 0.89 | ADRB2 (0.44) | MEN1KMT2AADRB2TARDBPRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198203-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2021-07-01 | — | — | US | claimed |
| US-20190352267-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2019-11-21 | — | — | US | claimed |
| US-20180305316-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2018-10-25 | — | — | US | claimed |
| EP-2862859-A2 | Compounds, compositions and methods | Cytokinetics, Inc. (US) | 2015-04-22 | — | — | EP | claimed |
| US-20150005296-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2015-01-01 | — | — | US | claimed |
| US-8110595-B2 | Ureas and their use in the treatment of heart failure | CYTOKINETICS, INC. (US) | 2012-02-07 | — | — | US | claimed |
| US-20090036447-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. (US) | 2009-02-05 | — | — | US | claimed |
| US-20060014761-A1 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | CYTOKINETICS, INCORPORATED | 2006-01-19 | — | — | US | claimed |
| US-12264133-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2025-04-01 | — | — | US | disclosed |
| US-20220185779-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2022-06-16 | — | — | US | disclosed |
| US-20210198203-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2021-07-01 | — | — | US | disclosed |
| US-10975034-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190352267-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2019-11-21 | — | — | US | disclosed |
| US-10385023-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-7507735-B2 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | CYTOKINETICS, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1959960-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070208000-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070161617-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
| WO-2007070683-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20060014761-A1 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | CYTOKINETICS, INCORPORATED | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161617-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | MEN1 4319/4885KMT2A 4052/4885ADRB2 372/4885 |
| US-20060014761-A1 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | TNNI3, MYLK2, TNNT2 | MEN1 4745/4885KMT2A 2999/4885ADRB2 1001/4885 |
| US-10385023-B2 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | MEN1 4344/4885KMT2A 4396/4885ADRB2 376/4885 |
| US-20220185779-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | MEN1 4344/4885KMT2A 4396/4885ADRB2 376/4885 |
| US-12264133-B2 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | MEN1 4344/4885KMT2A 4396/4885ADRB2 376/4885 |
| US-20190352267-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | MEN1 4344/4885KMT2A 4396/4885ADRB2 376/4885 |
| US-20070208000-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | MEN1 4319/4885KMT2A 4052/4885ADRB2 372/4885 |
| US-20150005296-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | MEN1 4344/4885KMT2A 4396/4885ADRB2 376/4885 |
| US-10975034-B2 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | MEN1 4344/4885KMT2A 4396/4885ADRB2 376/4885 |
| US-20090036447-A1 | Compounds, Compositions and Methods | TNNI3, TNNC1, TNNT2 | MEN1 4344/4885KMT2A 4396/4885ADRB2 376/4885 |
| US-20180305316-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | MEN1 4344/4885KMT2A 4396/4885ADRB2 376/4885 |
| US-20210198203-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | MEN1 4344/4885KMT2A 4396/4885ADRB2 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.